Propanc Health Group Corporation — Form 10-Q
Reporting period: Three months ended September 30, 2016, compared with the three months ended September 30, 2015. This is the company’s fiscal first quarter for the year ending June 30, 2017; it does not match the “2016 Q1” period in the request metadata. Financial statements are unaudited and reported in U.S. dollars.
Business context
Propanc is a development-stage biotechnology company working on pro-enzyme cancer treatments, with no products approved for sale, no products in clinical trials, and no revenue. Its reported activities included preclinical research, manufacturing preparation, and toxicology work.
Financial performance and position
| Metric | Three months ended September 30, 2016 | Comparable 2015 period |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $1,174,297 | $1,007,391 |
| Net loss | $1,101,969 | $838,894 |
| Net cash used in operations | $683,598 | $405,712 |
| Cash provided by financing | $614,286 | $415,338 |
Operating expenses comprised administration of $1,004,503, research and development of $161,197, and occupancy of $8,597. No operating margin is meaningful because the company reported no revenue. Basic and diluted loss per share was reported as $(0.00) in both periods.
At September 30, 2016, cash was $24,913, total current assets were $166,672, and total assets were $181,395. Current liabilities were $1,985,349, producing a working-capital deficit of $1,818,677. Stockholders’ deficit was $1,803,954 and accumulated deficit was $31,477,992. Convertible notes and accrued interest, net of discounts and premiums, were $546,571; the notes’ stated principal was $1,791,694 before unamortized discounts and other adjustments. Derivative liabilities totaled $832,592.
Changes and notable items
- Net loss rose by $263,075 year over year, while operating expenses increased by $166,906. Administration expense increased $155,524, primarily reflecting stock-based compensation.
- Interest expense increased to $471,387, including $444,835 of debt-discount amortization. A $369,373 gain from changes in derivative fair value and a $173,989 foreign-currency transaction gain partly offset expenses; foreign-currency translation produced a $224,819 comprehensive loss.
- Cash fell from $121,070 at June 30, 2016 to $24,913 at quarter-end. Financing included $150,000 of convertible-note proceeds and $464,286 from warrant exercises.
- Common shares outstanding increased from 728,616,312 at June 30 to 793,924,744 at September 30. The filing reported 811,511,724 shares outstanding as of November 10, 2016. Options, warrants, and convertible debt create further potential dilution.
Outlook, risks, and contingencies
- Going concern: Management reported substantial doubt about the company’s ability to continue as a going concern. It stated that available cash was insufficient for obligations over the following 12 months and that additional financing was required; there was no assurance financing would be available on acceptable terms.
- Financing and dilution: The Delafield debenture had been extended to February 28, 2017, with a $0.03 conversion price subject to a downward reset tied to trading prices. The company also issued 240 million warrants in connection with the extension and obtained an additional $150,000 Delafield loan in September. These instruments may result in substantial dilution; the debt is secured by company assets.
- Subsequent financing: On October 31, 2016, Eagle Equities purchased two 8% convertible notes of $100,000 each. One was cash-funded; funding of the back-end note was conditional. Conversion pricing is based on 60% of the lowest closing bid price over a specified 10-day period, and default interest is 24%.
- Development commitments: A Q-Biologicals manufacturing agreement contemplated $2.5 million to $5.0 million of payments over five years, primarily in the first two years, including an approximately $144,000 prepayment not yet made at quarter-end. The company said it could terminate early, but that prepayment would be non-refundable.
- Development and intellectual property risks: The lead product remained preclinical. Patent protection was granted in certain countries, while other applications remained pending or under examination. The company cited financing, development milestones, regulatory requirements, patent protection, dependence on third parties and key personnel, and cost control as risks.
- Controls: Management concluded disclosure controls were ineffective and reported material weaknesses involving the absence of an audit committee financial expert, limited technical accounting expertise, and inadequate segregation of duties. No material litigation was reported.
Important facts for investors to verify
- Whether the company obtained enough financing to meet near-term obligations and fund development, and the current status and terms of its convertible debt.
- The subsequent conversion activity, warrant exercises, registered share availability, and resulting outstanding and fully diluted share counts.
- Whether the Q-Biologicals prepayment and anticipated manufacturing costs were funded, and whether the program remains within the disclosed cost and timing expectations.
- Progress from preclinical work toward required toxicology studies and clinical trials, and the status of key patent applications.
- Whether management remedied the disclosed material weaknesses in financial reporting and disclosure controls.